SHKRELI TRIAL GOES TO THE JURY
Ajury will resume deliberations Tuesday at the federal securities fraud trial of Martin Shkreli, shown arriving at U.S. District Court on Monday with his attorney. The 34-year-old former biotech CEO is notorious for buying the rights to a drug called Daraprim and promptly raising the price by 5,000 percent, and for trolling his critics on social media. The deliberations follow about a month of testimony in federal court in New York City, most of it from investors in two failed hedge funds run by the defendant. The defense argued that the investors weren’t victims because they recouped their money when the drug company went public.
Drew Angerer, Getty Images